National Health Education Lupus Program (NHELP)

archived

The purpose of NHELP is to reduce lupus related health disparities among racial and ethnic minority and/or disadvantaged populations disproportionately affected by this disease by (1) conducting a national health education program on lupus (Priority A) and (2) initiating an education action plan on clinical trials targeted at minority and/or disadvantaged populations, especially those most disproportionally affected by lupus. Three to four grantees will be funded to conduct Priority A of this national initiative. One grantee will be funded to conduct Priority B of this national initiative.Priority A is designed to improve outreach and education efforts in the targeted community(ies) to increase awareness and understanding of lupus and management of primary and secondary conditions using culturally and linguistically appropriate materials and models, and engage health care providers, educators, and health professions schools in improving lupus diagnosis and treatment in minority and/or disadvantaged populations. Priority B is designed to develop an education action plan on minority and/or disadvantaged populations’ participation in clinical trials for lupus and begin preliminary steps toward its implementation focusing on improving recruitment and retention rates in clinical trials for minority and/or disadvantaged populations affected by lupus. This priority activity will focus on developing public-private and community partnerships to address minority and/or disadvantaged populations’ participation in clinical trials; evaluating current clinical trial education, recruitment, and participation initiatives for minority and/or disadvantaged populations; developing innovative education program models on clinical trial participation for minority and/or disadvantaged populations that are culturally and linguistically appropriate for the targeted population(s); and developing an action plan for disseminating these education models to increase minority and/or disadvantaged populations’ participation in lupus clinical trials.

High